Obesity and inflammation markers in relation to leukocyte telomere length in a cross-sectional study of persons with Barrett's esophagus

BMC Obesity

Volumn 2, Issue 1, 2015, Pages

  Hardikar, Sheetal ^a,b,c   Song, Xiaoling ^a   Risques, Rosa Ana ^b   Montine, Thomas J ^b   Duggan, Catherine ^a   Blount, Patricia L ^a,b   Reid, Brian J ^a,b   Anderson, Garnet L ^a,b   Kratz, Mario ^a,b   White, Emily ^a,b   Vaughan, Thomas L ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Fred Hutchinson Cancer ResearchCenter ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GENOMIC DNA; GLUCOSE; INSULIN; INTERLEUKIN 6; ISOPROSTANE DERIVATIVE; LEPTIN; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BARRETT ESOPHAGUS; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DNA EXTRACTION; FEMALE; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; INFLAMMATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MASS FRAGMENTOGRAPHY; MIDDLE AGED; OBESITY; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE STUDY; RADIOIMMUNOASSAY; TELOMERE LENGTH; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

EID: 84966363000     PISSN: None     EISSN: 20529538     Source Type: Journal    
DOI: 10.1186/s40608-015-0063-3     Document Type: Article

References (38)

1. McEachern MJ, Krauskopf A, Blackburn EH. Telomeres and their control. Annu Rev Genet. 2000;34:331-58. doi:10.1146/annurev.genet.34.1.331.
2. Wong JM, Collins K. Telomere maintenance and disease. Lancet. 2003;362(9388):983-8. doi:10.1016/S0140-6736(03)14369-3.
3. Bekaert S, De Meyer T, Rietzschel ER, De Buyzere ML, De Bacquer D, Langlois M, et al. Telomere length and cardiovascular risk factors in a middle-aged population free of overt cardiovascular disease. Aging Cell. 2007;6(5):639-47. doi:10.1111/j.1474-9726.2007.00321.x.
4. Fitzpatrick AL, Kronmal RA, Gardner JP, Psaty BM, Jenny NS, Tracy RP, et al. Leukocyte telomere length and cardiovascular disease in the cardiovascular health study. Am J Epidemiol. 2007;165(1):14-21. doi:10.1093/aje/kwj346.
5. Hunt SC, Chen W, Gardner JP, Kimura M, Srinivasan SR, Eckfeldt JH, et al. Leukocyte telomeres are longer in African Americans than in whites: the national heart, lung, and blood institute family heart study and the Bogalusa heart study. Aging Cell. 2008;7(4):451-8. doi:10.1111/j.1474-9726.2008.00397.x.
6. Valdes AM, Andrew T, Gardner JP, Kimura M, Oelsner E, Cherkas LF, et al. Obesity, cigarette smoking, and telomere length in women. Lancet. 2005;366(9486):662-4. doi:10.1016/S0140-6736(05)66630-5.
7. Sanders JL, Newman AB. Telomere length in epidemiology: a biomarker of aging, Age-related disease, both, or neither? Epidemiol Rev. 2013. doi:10.1093/epirev/mxs008.
8. Salpea KD, Talmud PJ, Cooper JA, Maubaret CG, Stephens JW, Abelak K, et al. Association of telomere length with type 2 diabetes, oxidative stress and UCP2 gene variation. Atherosclerosis. 2010;209(1):42-50. doi:10.1016/j. atherosclerosis. 2009.09.070.
9. Meeker AK, Hicks JL, Iacobuzio-Donahue CA, Montgomery EA, Westra WH, Chan TY, et al. Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin Cancer Res. 2004;10(10):3317-26. doi:10.1158/1078-0432.CCR-0984-03.
10. Willeit P, Willeit J, Mayr A, Weger S, Oberhollenzer F, Brandstatter A, et al. Telomere length and risk of incident cancer and cancer mortality. JAMA. 2010;304(1):69-75. doi:10.1001/jama.2010.897.
11. Wentzensen IM, Mirabello L, Pfeiffer RM, Savage SA. The association of telomere length and cancer: a meta-analysis. Cancer Epidemiol Biomark Prev. 2011;20(6):1238-50. doi:10.1158/1055-9965.EPI-11-0005.
12. Risques RA, Vaughan TL, Li X, Odze RD, Blount PL, Ayub K, et al. Leukocyte telomere length predicts cancer risk in Barrett's esophagus. Cancer Epidemiol Biomarkers Prevention. 2007;16(12):2649-55. doi:10.1158/1055-9965.EPI-07-0624.
13. Hou L, Savage SA, Blaser MJ, Perez-Perez G, Hoxha M, Dioni L, et al. Telomere length in peripheral leukocyte DNA and gastric cancer risk. Cancer Epidemiol Biomark Prev. 2009;18(11):3103-9. doi:10.1158/1055-9965.EPI-09-0347.
14. Chung HY, Kim HJ, Kim JW, Yu BP. The inflammation hypothesis of aging: molecular modulation by calorie restriction. Ann N Y Acad Sci. 2001;928:327-35.
15. Carrero JJ, Stenvinkel P, Fellstrom B, Qureshi AR, Lamb K, Heimburger O, et al. Telomere attrition is associated with inflammation, low fetuin-A levels and high mortality in prevalent haemodialysis patients. J Intern Med. 2008;263(3):302-12. doi:10.1111/j.1365-2796.2007.01890.x.
16. O'Donovan A, Pantell MS, Puterman E, Dhabhar FS, Blackburn EH, Yaffe K, et al. Cumulative inflammatory load is associated with short leukocyte telomere length in the health, aging and body composition study. PLoS One. 2011;6(5):e19687. doi:10.1371/journal.pone.0019687.
17. Houben JM, Moonen HJ, van Schooten FJ, Hageman GJ. Telomere length assessment: biomarker of chronic oxidative stress? Free Radic Biol Med. 2008;44(3):235-46. doi:10.1016/j.freeradbiomed.2007.10.001.
18. Zimmermann MB, Aeberli I. Dietary determinants of subclinical inflammation, dyslipidemia and components of the metabolic syndrome in overweight children: a review. Int J Obes. 2008;32 Suppl 6:S11-8. doi:10.1038/ijo.2008.202.
19. Aviv A. Telomeres and human aging: facts and fibs. Sci Aging Knowledge Environ. 2004;2004(51), e43. doi:10.1126/sageke.2004.51.pe43.
20. Souza R, Spechler S. Concepts in the prevention of adenocarcinoma of the distal esophagus and proximal stomach. CA Cancer J Clin. 2005;55(6):334-51.
21. Reid BJ, Li X, Galipeau PC, Vaughan TL. Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer. 2010;10:87-101.
22. Hardikar S, Onstad L, Blount PL, Odze RD, Reid BJ, Vaughan TL. The role of tobacco, alcohol, and obesity in neoplastic progression to esophageal adenocarcinoma: a prospective study of Barrett's esophagus. PLoS One. 2013;8(1):e52192. doi:10.1371/journal.pone.0052192.
23. Vaughan TL, Dong LM, Blount PL, Ayub K, Odze RD, Sanchez CA, et al. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol. 2005;6(12):945-52. doi:10.1016/S1470-2045(05)70431-9.
24. Kantor ED, Onstad L, Blount PL, Reid BJ, Vaughan TL. Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett's esophagus. Cancer Epidemiol Biomark Prev. 2012;21(3):456-61. doi:10.1158/1055-9965.EPI-11-1014.
25. Hardikar S, Song X, Kratz M, Anderson GL, Blount PL, Reid BJ, et al. Intraindividual variability over time in plasma biomarkers of inflammation and effects of long-term storage. Cancer Causes Control. 2014. doi:10.1007/s10552-014-0396-0.
26. Hardikar S, Onstad L, Song X, Wilson AM, Montine TJ, Kratz M, et al. Inflammation and oxidative stress markers and esophageal adenocarcinoma incidence in a Barrett's esophagus cohort. Cancer Epidemiol Biomarkers Prevention. 2014;23(11):2393-403. doi:10.1158/1055-9965.epi-14-0384.
27. Duggan C, Onstad L, Hardikar S, Blount PL, Reid BJ, Vaughan TL. Association between markers of obesity and progression from Barrett's esophagus to esophageal adenocarcinoma. Clin Gastroenterol Hepatol. 2013. doi:10.1016/j.cgh.2013.02.017.
28. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res. 2002;30(10), e47.
29. Box HC, O'Connor RJ, Patrzyc HB, Iijima H, Dawidzik JB, Freund HG, et al. Reduction in oxidatively generated DNA damage following smoking cessation. Tob Induc Dis. 2011;9:1. doi:10.1186/1617-9625-9-5.
30. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999;19:972-8.
31. Batty GD, Wang Y, Brouilette SW, Shiels P, Packard C, Moore J, et al. Socioeconomic status and telomere length: the West of Scotland coronary prevention study. J Epidemiol Community Health. 2009;63(10):839-41. doi:10.1136/jech.2009.088427.
32. Wong JY, De Vivo I, Lin X, Fang SC, Christiani DC. The relationship between inflammatory biomarkers and telomere length in an occupational prospective cohort study. PLoS One. 2014;9(1), e87348. doi:10.1371/journal.pone.0087348.
33. Franceschi C, Bonafe M, Valensin S, Olivieri F, De Luca M, Ottaviani E, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000;908:244-54.
34. Rodier F, Coppe JP, Patil CK, Hoeijmakers WA, Munoz DP, Raza SR, et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol. 2009;11(8):973-9. doi:10.1038/ncb1909.
35. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer. 2009;9(5):361-71. doi:10.1038/nrc2628.
36. Diaz VA, Mainous AG, Player MS, Everett CJ. Telomere length and adiposity in a racially diverse sample. Int J Obes. 2010;34(2):261-5. doi:10.1038/ijo.2009.198.
37. Broer L, Raschenberger J, Deelen J, Mangino M, Codd V, Pietilainen KH, et al. Association of adiponectin and leptin with relative telomere length in seven independent cohorts including 11,448 participants. Eur J Epidemiol. 2014;29(9):629-38. doi:10.1007/s10654-014-9940-1.
38. Barbieri M, Paolisso G, Kimura M, Gardner JP, Boccardi V, Papa M, et al. Higher circulating levels of IGF-1 are associated with longer leukocyte telomere length in healthy subjects. Mech Ageing Dev. 2009;130(11-12):771-6. doi:10.1016/j.mad.2009.10.002.